Rafferty Asset Management
ORIC icon

Rafferty Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Rafferty Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$983K Sell
90,763
-24,717
-21% -$224K ﹤0.01% 792
2026
Q1 		$1.46M Sell
115,480
-61,699
-35% -$700K 0.01% 674
2025
Q4 		$1.45M Buy
177,179
+91,587
+107% +$1.05M 0.01% 724
2025
Q3 		$1.03M Buy
85,592
+42,948
+101% +$452K ﹤0.01% 787
2025
Q2 		$433K Sell
42,644
-34,780
-45% -$233K ﹤0.01% 913
2025
Q1 		$432K Buy
77,424
+26,032
+51% +$228K ﹤0.01% 898
2024
Q4 		$415K Sell
51,392
-13,193
-20% -$121K ﹤0.01% 948
2024
Q3 		$662K Sell
64,585
-51,623
-44% -$510K ﹤0.01% 879
2024
Q2 		$822K Buy
116,208
+5,062
+5% +$45.3K ﹤0.01% 858
2024
Q1 		$1.53M Buy
+111,146
New +$1.32M 0.01% 753
2022
Q1 		– Sell
-68,423
Closed -$1.01M – 1300
2021
Q4 		$1.01M Buy
68,423
+37,112
+119% +$579K 0.01% 857
2021
Q3 		$655K Sell
31,311
-16,323
-34% -$331K ﹤0.01% 983
2021
Q2 		$843K Sell
47,634
-19,730
-29% -$432K 0.01% 965
2021
Q1 		$1.65M Buy
+67,364
New +$2.13M 0.01% 674

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rafferty Asset Management's ORIC Position: Q2 2026 in Review

Rafferty Asset Management reduced its Oric Pharmaceuticals (ORIC) stake by 21% in Q2 2026, selling an estimated $224K and leaving 90,763 shares worth $983K. The position accounts for ﹤0.01% of the portfolio, ranked #792.

Rafferty Asset Management first reported a position in ORIC in Q1 2021 and has held it in 14 quarters since. The position peaked at $1.65M in Q1 2021. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Rafferty Asset Management held 90,763 shares of Oric Pharmaceuticals worth $983K as of Q2 2026.
  • Rafferty Asset Management sold 24,717 Oric Pharmaceuticals shares in Q2 2026, an estimated $224K.
  • Oric Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #792 holding.
  • Rafferty Asset Management first reported a position in Oric Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
  • Rafferty Asset Management's Oric Pharmaceuticals position peaked at $1.65M in Q1 2021.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.